Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib vs Pemetrexed Maintenance in Advanced Non-Squamous NSCLC
NCT01313663Phase 2Terminated
- Sponsor
- GSK
- Start
- Feb 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in non-small cell lung cancer (NSCLC), sponsored by GSK. Started Feb 2011; status: terminated.
02
Drugs
pazopanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01313663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313663.